HMNC completes subject randomisation in Phase IIb MDD treatment trial

Retrieved on: 2025-01-13 16:56:03

Tags for this article:

Mood disorders

Vasopressin receptor 1B

Major depressive disorder

Vasopressin

Click the tags to see associated articles and topics

HMNC completes subject randomisation in Phase IIb MDD treatment trial. View article details on hiswai:

Summary

The article discusses HMNC Brain Health's Phase IIb trial of BH-200, a biopharma drug targeting vasopressin receptor 1B, for treating major depressive disorder linked to mood disorders. The study aligns closely with the provided key concept and tags.

Article found on: www.clinicaltrialsarena.com

View Original Article